denosumab

Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Yahoo/Benzinga
Amgen
Sandoz
legal
Prolia
Xgeva
patents
denosumab
Flag link:
Amgen's denosumab shows promise in small, NIH-funded rare bone disease study
Amgen's denosumab shows promise in small, NIH-funded rare bone disease study
Endpoints
Amgen
Prolia
Xgeva
denosumab
clinical trials
NIH
biosimilars
monoclonal antibodies
Flag link:
Sandoz reports data from Phase I/III trial of denosumab for osteoporosis
Sandoz reports data from Phase I/III trial of denosumab for osteoporosis
Clinical Trials Arena
Novartis
Sandoz
clinical trials
biosimilarts
denosumab
osteoporosis
Flag link:
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Pharmaceutical Business Review
Novartis
Sandoz
biosimilars
clinical trials
denosumab
osteoporosis
Prolia
Xgeva
Flag link:
Amgen's Xgeva Wins EU Approval
Amgen's Xgeva Wins EU Approval
Yahoo/Zacks.com
Amgen
Xgeva
Europe
GSK
denosumab
Novartis
Flag link:
Amgen Pushes Ahead With "Son of Dmab" for Treating Bones
Amgen Pushes Ahead With "Son of Dmab" for Treating Bones
Motley Fool
Amgen
AMG785
denosumab
osteoporosis
Flag link:
Amgen Presents New XGEVA (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
Amgen Presents New XGEVA (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
Yahoo/PR NewsWire
Amgen
denosumab
Xgeva
breast cancer
Flag link:
One Drug, Two Names, Two Wildly Different Prospects
One Drug, Two Names, Two Wildly Different Prospects
Motley Fool
Amgen
Prolia
Xgeva
denosumab
Flag link:
Amgen's Bone Drug Denosumab Cleared to Treat Fractures in Cancer Patients
Amgen's Bone Drug Denosumab Cleared to Treat Fractures in Cancer Patients
Bloomberg
Amgen
denosumab
cancer
Flag link:
Amgen Drug May Block Some Breast Cancer, Studies Hint
Amgen Drug May Block Some Breast Cancer, Studies Hint
Bloomberg
Amgen
breast cancer
denosumab
Flag link:
Amgen gets rapid FDA review for denosumab
Amgen gets rapid FDA review for denosumab
Yahoo/AP
Amgen
FDA
Prolia
denosumab
Flag link:
Amgen drug gets priority review for bone cancer
Amgen drug gets priority review for bone cancer
Marketwatch
bone cancer
Amgen
FDA
denosumab
Prolia
Flag link:
FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal Related Events in Advanced Cancer Patients
FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal Related Events in Advanced Cancer Patients
Yahoo/PR NewsWire
Amgen
denosumab
skeletal metastases
Flag link:
Amgen Gets FDA Approval and SonoSite Has a New Frontier
Amgen Gets FDA Approval and SonoSite Has a New Frontier
Motley Fool
Amgen
denosumab
Prolia
SonoSite
ultrasound
Flag link:
Amgen Highlights Key Clinical Data to Be Presented at American Society of Clinical Oncology Annual Meeting
Amgen Highlights Key Clinical Data to Be Presented at American Society of Clinical Oncology Annual Meeting
PR-USA
Amgen
denosumab
zoledronic acid
Bone metastases
prostate cancer
Flag link:
Amgen’s Crop of Experimental Cancer Drugs Shows Initial Results
Amgen’s Crop of Experimental Cancer Drugs Shows Initial Results
Bloomberg
Amgen
cancer
pancreatic cancer
ovarian cancer
pipelines
denosumab
Flag link:
Amgen (AMGN) Submits BLA to U.S. FDA for Denosumab RANK Inhibitor
Amgen (AMGN) Submits BLA to U.S. FDA for Denosumab RANK Inhibitor
Street Insider
Amgen
BLA
FDA
denosumab
RANK Ligand inhibitor
Flag link:
Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients
Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients
Amgen, PR NewsWire
Amgen
denosumab
Bone metastases
Flag link:
A Cautious Look at Amgen's Denosumab
A Cautious Look at Amgen's Denosumab
Seeking Alpha
Amgen
denosumab
Flag link:
Amgen Gets More Good Data with Bone Drug Prolia, but Other Risks Await
Amgen Gets More Good Data with Bone Drug Prolia, but Other Risks Await
BNET Pharma
Amgen
Prolia
Novartis
Zometa
denosumab
Flag link:

Pages